Step by Step


ABIM and DOB Data Collection

1/17/23 - Medical Grand Rounds: Myositis and the Anti-Synthetase Syndrome: Bedside to Bench . . . and Back?





Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Describe the clinical features of the anti-synthetase syndrome.
  • Recognize features characteristic of autoimmune interstitial lung disease.
  • Define the role of Jo-1 (HRS) in the immunopathogenesis of the anti-synthetase syndrome.
  • Identify key innate and adaptive immune signaling pathways contributing to a murine model of HRS-induced myositis
  • Devise new therapeutic strategies based on overlap between murine model and human disease

Suggested Additional Reading & Joint Accreditation Statement - Note: This Accreditation Statement Supersedes All Other Statements:

Suggested additional reading:

  1. Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, Oddis CV. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 73(1):227-232, 2014.
  2. Gallay L, Gayed C, Hervier B.  Antisynthetase syndrome pathogenesis: knowledge and uncertainties.; Curr Opin Rheumatol. 2018 Nov;30(6):664-673. doi: 10.1097/BOR.0000000000000555
  3. Afzali AM, Ruck T, Wiendl H, Meuth SG.  Animal models in idiopathic inflammatory myopathies: How to overcome a translational roadblock?  Autoimmun Rev. 2017 May;16(5):478-494. doi: 10.1016/j.autrev.2017.03.001. Epub 2017 Mar 7

Joint Accreditation Statement

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit[s]™. Physicians should only claim credit commensurate with the extent of their participation in the activity. This educational activity is approved for 1.0 contact hours.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Chester Oddis, MD — Professor of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine
Dr. Oddis receives grant/research support from Genentech, CSL Behring, and Mallinckrodt. Dr. Oddis is a consultant with Pfizer and EMD Serono.
Dana Ascherman, MD — Professor of Medicine, Chief, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine
Dr. Ascherman receives grant/research support from Mallinckrodt, TEVA, Argenx, and Biogen. They are also a consultant for PTC Therapeutics, Lundbeck, and EMD Serono.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity is approved for AMA PRA Category 1 Credit™

The University of Pittsburgh is an affirmative action, equal opportunity institution.